Skip to content

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04833465
Enrollment
90
Registered
2021-04-06
Start date
2021-07-16
Completion date
2028-12-01
Last updated
2026-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibromyalgia, Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus

Brief summary

The overarching goal of this study is the development of a physiologic endpoint of pain and treatment effect in three distinct rheumatology populations. This would enable objective assessment of pain and treatment in these populations and enable a much more precise approach to treatment. Such an endpoint stands to significantly improve outcomes in these patients by eliminating the need for a trial-and-error approach to treatment. This is a single site observational study that aims to collect initial pilot data in three distinct patient groups. As this is observational, there is no randomization or blinding in the study. Patients will be followed for a period of one year after enrollment. Baseline measurements will be taken at the time of enrollment, and at each subsequent standard of care clinic visit as feasible, for a period of one year. As this is an observational study, there will be no change to the treatment for any patient due to research activities. The primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations. The secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.

Interventions

OTHERNo Intervention

No Intervention

Sponsors

Children's National Research Institute
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
5 Years to 21 Years
Healthy volunteers
No

Inclusion criteria

In order to be eligible for inclusion in the study, an individual must meet all of the following criteria: * Male or female ≥ 5 years of age at screening. * Documentation of a JIA, SLE or FM diagnosis as evidenced by history

Exclusion criteria

Any individual who meets any of the following criteria will be excluded from participation in this study: • Documented history of eye disease precluding pupillometry

Design outcomes

Primary

MeasureTime frameDescription
Index Characterization1 YearThe primary objective of this study is the characterization of the nociceptive index in three pediatric rheumatology populations.

Secondary

MeasureTime frameDescription
Treatment Effect1 YearThe secondary objective is the characterization of the nociceptive index in these populations in response to standard of care interventions. This is necessary to demonstrate the ability of this approach to serve as an endpoint of treatment effect.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 25, 2026